[Monthly prevalence of generalized anxiety disorder during the Covid-19 pandemic in Mexico]

Salud Publica Mex. 2021 Jun 18;63(4):478-485. doi: 10.21149/12257.
[Article in Spanish]

Abstract

Objective. Estimate the prevalence of generalized anxiety disorder (GAD) from April to June 2020. Materials and methods. Repeated cross-sections design based in the Encovid-19, a series of monthly mobile surveys with representative samples of Mexico (N= 833-1 674). The questionnaire includes the GAD-2 scale, and, in July, the GAD-7 scale was added; we examined its internal validity with confirmatory factor analysis and its concurrent validity with sociodemographic variables. Using GAD-7 as criterion, we analyzed the predictive validity of the GAD-2. We estimated the monthly prevalence with the GAD-2. Results. The GAD-7 and the GAD-2 are reliable and valid. The GAD-2 has a sensitivity of 0.87 and a specificity of 0.90. The monthly prevalence remains high and stable, between 30.7 and 32.6%. GAD concentrated in women, unemployed and persons with low socioeconomic status. Conclusions. GAD is a public health problem that worsened during the Covid-19 pandemic.

Keywords: Covid-19; GAD; anxiety; monitoring; validity.

MeSH terms

  • Anxiety
  • Anxiety Disorders / epidemiology
  • COVID-19*
  • Female
  • Humans
  • Mexico / epidemiology
  • Pandemics*
  • Prevalence
  • SARS-CoV-2